Cellectis (NASDAQ: CLLS) pivots to in vivo gene editing, extending cash runway to H2 2028. Read pipe

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock?

Allogene Therapeutics, Inc. (ALLO) Presents at Citigroup's Biopharma Back to School Summit 2026 Tran

Frazier Life Sciences Management L.P. boosted its stake in shares of Allogene Therapeutics, Inc. (NA

Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the dev

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq:

Deutsche Bank AG bought a new stake in Allogene Therapeutics, Inc. (NASDAQ: ALLO) in the undefined q

Connor Clark and Lunn Investment Management Ltd. purchased a new position in shares of Allogene Ther

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq:

Cema-cel produced MRD clearance in 58.3% of treated patients versus 16.7% under observation. The 97.

Bank of America Corp DE lifted its position in shares of Allogene Therapeutics, Inc. (NASDAQ: ALLO)

Here is how Allogene Therapeutics (ALLO) and Brainsway Ltd. Sponsored ADR (BWAY) have performed comp

Citizens analyst Reni J. Benjamin reiterates Allogene Therapeutics (NASDAQ:ALLO) with a Market Ou

ALLO narrows its Q2 loss as R&D costs fall, while a stronger cash position extends its runway into 2

Dimensional Fund Advisors LP grew its stake in Allogene Therapeutics, Inc. (NASDAQ: ALLO) by 25.5% i

Allogene Therapeutics, Inc. (ALLO) Q2 2026 Earnings Call Transcript

Allogene Therapeutics NASDAQ: ALLO outlined progress across its clinical pipeline during its second-

Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.13) per share which beat the an

SOUTH SAN FRANCISCO, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq:

SOUTH SAN FRANCISCO, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq:

Shares of Allogene Therapeutics, Inc. (NASDAQ: ALLO - Get Free Report) have earned an average recomm

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering alloge

FDA Granted RMAT Designation Based on ALPHA3 Trial Futility Analysis, Highlighting Cema-Cel's Potent

Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the dev

ALLO-316 Achieved a 31% Confirmed Response Rate with the Recommended Phase 2 Regimen in Patients wit

Allogene Therapeutics offers upside potential driven by the pivotal ALPHA3 trial for Cema-cel in fir

Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.18) per share which beat the an

Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the dev

U.S. stocks were mixed on Thursday, with the Dow Jones gaining 0.1%. Aehr Test Systems shares rose 1

Analysts change outlook on top names: Mizuho downgrades PYPL, B of A increases CIEN PT, Needham rais

US stocks rise, Nasdaq up 200 points; Tech shares lead gains. Morgan Stanley beats estimates. Allbir

US stock futures mixed, Nasdaq 100 up over 50 points. JPMorgan shares down 3.1% after beating earnin

Top Wall Street analysts have changed their outlook on top names. For full analyst rating changes, i

Allogene's ALPHA3 trial shows strong MRD clearance and ctDNA reduction, signaling potential to d

U.S. stocks were mixed on Monday, with the Dow Jones falling over 200 points. Leggett & Platt ro

IDEAYA Biosciences shares (NASDAQ: IDYA) jumped 18% in pre-market trading after announcing topline

U.S. stock futures lower, Dow futures down 300 points. Worthington Steel Inc (NYSE: WS) shares fall

Stocks fall, Nasdaq drops 200 points. Apogee Therapeutics (APGE) rises 19.4% on positive trial data.

U.S. stocks higher as Dow Jones gains 300 points; El Pollo LoCo Holdings jumps 17.6% on better-than-